Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.

Affiliations

¹ Department of Experimental and Clinical Medicine, and Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), University of Florence, Careggi University Hospital, Florence.
² Department of Experimental and Clinical Medicine, University of Florence, and Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital, Florence, Italy.
³ Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
⁴ Department of Experimental and Clinical Medicine, University of Florence, and Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 / immunology
COVID-19 / prevention & control
COVID-19 Vaccines / administration & dosage*
COVID-19 Vaccines / immunology
Humans
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / immunology*
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
SARS-CoV-2 / immunology

Substances

COVID-19 Vaccines
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Grants and funding